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Use and Abuse of Coronary Stenting
Bernhard Meier, MD
A B S T R A C T
The introduction of the coronary stent in 1986 remains the only real asset to bal-
loon angioplasty introduced about 10 years earlier. Unfortunately, the undeniable 
advantages of stenting in terms of preventing abrupt closure and reducing restenosis 
are not fully exploited. The prognostic benefit to be expected from judicious stenting 
has been given up by default stenting. Infarctions and lives saved initially by stenting 
are lost again by stent thrombosis after hospital discharge fraught with a mortality of 
about 50% by late infarctions. They do not exist after plain balloon angioplasty and 
are due to stent thrombosis. Because of the comfort benefit that prevails (reduced 
need for intervention), virtually all interventional cardiologists have subscribed to a 
policy of 100% stenting and are currently about to adopt active (drug eluting) stents 
as their default devices for it. Once more, active stents do not confer any prognostic 
benefit over passive stents but they further reduce restenosis and are appealing to op-
erators and patients. Evidence based medicine condones stenting only in about 50% 
and active stents in may be 80%. Yet this is ignored for rather irrational reasons. 
I N T R O D U C T I O N
Coronary stents were developed in the early eighties primarily to remedy (bail-out) 
abrupt vessel closure during coronary angioplasty (PCI). The first stent implanta-
tion was performed by Jacques Puel on March 28, 1986 electively in a patient with a 
restenosis after coronary balloon angioplasty [1]. Although reduction of restenosis 
had been in the back of the minds of the stent developers [1-4], scaffolding intimal 
flaps was the primary task [3]. The publication launching widespread clinical use of 
coronary stents [4], however, already put prevention of restenosis in the forefront. It 
had turned out that the prevention of elastic recoil by the stent more than compen-
sated for the disadvantage of more intimal proliferation induced by the foreign body 
implanted upon the lacerated endothelium of the coronary lesion.
B A R E  S T E N T S  V E R S U S  B A L L O O N  A N G I O P L A S T Y  
The initial (non-randomized) comparisons between plain balloon angioplasty and 
bare stents showed a marked safety advantage of the stents (Figure 1) [5,6]. Nonetheless, 
stenting took off slowly because of a misconception of many an interventional cardiolo-
gist. Stenting was initially used almost exclusively for salvaging complications or bad 
results after balloon angioplasty. This resulted in rather dismal outcomes of the stented 
patients [7]. One-year-results with a mortality of 8% and 24% stent occlusions were 
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no match for general balloon angioplasty results. Only when 
randomized trials using stents in one arm in all patients proved 
a significant advantage of stenting over balloon angioplasty in 
terms of soft endpoints, such as need for re-intervention [8,9], 
interventional cardiologists literally jumped on this technique, 
adopting default stenting within a few years. Nobody seemed 
to question why there no longer was an advantage in the 
most important endpoints such as mortality and myocardial 
infarction [10,11]. All seemed content with the conspicuous 
reduction in need for emergency coronary bypass surgery and 
later revascularizations of any kind. After full implementation 
of routine coronary stenting, a continuous European registry 
encompassing data of a population over 500 patients showed 
no decrement in mortality or myocardial infarction (Figure 
2) [12]. The stents had certainly helped to reduce the need 
for emergency coronary artery bypass surgery. However, the 
trend to resort less often to such a drastic measure had already 
started before the introduction of coronary stents. Mortality 
rates of 20%-50% in patients undergoing emergency coronary 
artery bypass surgery had made clear that this procedure was 
not beneficial in all angioplasty procedures that ended with 
a poor local result or even an occluded coronary artery [13]. 
The lack of impact on prognostic endpoints such as morta-
lity and infarction has to be blamed on the overuse of stents. 
First, the obsession to put a stent into every lesion leads to 
additional complications as it prolongs to procedure and im-
parts additional trauma to the coronary arteries on the way 
to the lesion to be stented. Second, side branches in jeopardy 
actually occluded in 5% in the pre-stent era [14] but in about 
20% when stents were generously used [15]. These data did 
not even account for the new and grave problem that stents 
introduced, i.e., late thrombotic occlusion of the treated site. 
Even with bare stents, this problem that has been talked about 
little before active (drug eluting) stents were introduced was 
there and occurred in about 2% [16] of cases, while it had 
been virtually inexistent before stents were available. Hence, 
the interventional cardiology community appeared to behave 
rationally by abstaining from expanding their activity in a 
single session to too many vessels. In fact, figure 3 shows that 
multivessel angioplasty in a single session did not increase 
from 1992-2003 [12].
The impression that stenting had made coronary an-
gioplasty more comfortable for both operators (nicer an-
giographic results, less concern about abrupt closure in the 
catheterization laboratory or before hospital discharge) and 
patients (less need for a re-intervention) but not safer (this 
latter point was usually played down if not blatantly denied) 
was corroborated by a meta-analysis of randomized trials be-
tween balloon angioplasty and coronary stenting using bare 
(passive) stents [17]. On the basis of the stenting rates used in 
the balloon arm which varied according to the bravery of the 
operators from 0% to 60%, this meta-analysis proved that the 
need for repeat angioplasty could indeed be reduced from 16% 
to about 5% but the bulk of the effect was already attained 
at a stenting rate of about 20%. This was based on 29 trials 
encompassing 9,918 patients and made perfect sense but it was 
largely ignored by interventional cardiologists. Without even 
having to analyze such a large host of patients, one could have 
estimated a similar percentage of stenting yielding virtually the 
full benefit. Before stenting, 70% of patients neither had an 
FIGURE 1. Non-randomized comparison of complications on 
1,801 patients with plain balloon angioplasty of whom 122 (7%) 
suffered a threatened or accomplished abrupt closure [5] and 
4,595 patients of whom 339 (7%) had a threatened or accom-
plished abrupt closure that was treated with stent implantation 
[6]. There is a highly significant stent advantage in terms of 
mortality (death) myocardial infarction (MI), or the need for 
emergency coronary bypass surgery (CABG) before hospital 
discharge.
FIGURE 2. In-hospital mortality (left panel), myocardial infarc-
tion (center panel), or need for emergency coronary bypass sur-
gery (right panel) in a comprehensive European registry from 
1992-2003 [12]. In spite of full adoption of coronary stenting, 
only the need for bypass surgery decreased significantly.
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acute nor a chronic problem after balloon angioplasty such as 
a vessel occlusion or restenosis. In these 70%, stenting cannot 
possibly improve the outcome but it can deteriorate it, e.g., by 
adding the risk of late stent thrombosis unknown to balloon 
angioplasty. Assuming that 5% to 10% of these patients would 
have a problem in spite of being equipped with a stent, the 20% 
rate found by the meta-analysis [17] is accurately forecast. It is 
understandable that no interventional cardiologist will operate 
with a 20% stenting rate as the patients finally benefiting from 
a stent are difficult to predict. However, it looks amateurish 
(and is not in the interest of patients overall) to not even try 
to predict them and insert stents in 100% of patients. A true 
professional should be able to stent no more than half of his 
patients and still have the vast majority of those needing a 
stent among the ones also receiving it. A non-randomized 
study comparing a stenting rate of 70% by one operator to a 
stenting rate of 50% by another one in the same interventional 
group, found no difference in over 300 patients pertaining to 
in-hospital or 1-year mortality, major adverse cardiac events, 
or restenosis [18].
Another new feature brought about by stenting was initially 
ignored. In-stent restenosis occurred less often than restenosis 
without a stent. However, some of these restenoses were dif-
fuse and much more difficult to treat than a restenosis after 
plain balloon angioplasty. Hence studies comparing resteno-
sis after balloon angioplasty or stenting should have used a 
conversion factor counting double each in-stent restenosis (or 
at least the diffuse ones). Only when a new method to treat 
that problem (brachytherapy) was introduced, this problem 
was brought to light. Notwithstanding, brachytherapy never 
stood a chance to become a routine procedure. One had to 
irradiate about 10 patients to save 1 from an additional inter-
vention, hardly a bargain considering the wasted money and 
time used in the 9 patients who would not have had a further 
problem with a simple balloon dilatation or had one in spite 
of brachytherapy. Yet, to bring out the advantages of their 
technique, protagonists of brachytherapy emphasized the 
intricacy of in-stent restenosis.
A C T I V E  ( D R U G  E L U T I N G )  V E R S U S  
P A S S I V E  ( B A R E )  S T E N T S
Putting drugs on stents that reduce the intimal prolifera-
tion was a logical thing to do because the foreign material 
increased the tendency for endothelial overgrowth. In small 
vessels, such as the coronary arteries, 1 mm of overgrowth 
(also named late loss) means a decrease in the lumen of 2 mm 
translating into a stenosis of at least 50%. After the initial 
results of the RAVEL trial showing no restenosis whatsoever 
with active stents, a veritable frenzy broke out. Strangely, the 
very bare stents that had had a low recurrence rate when they 
had been compared with plain balloon angioplasty all of a 
sudden were reported with recurrence rates in the realm previ-
ously typical for balloon angioplasty (Figures 4, 5) [19].
As with the transition from balloon angioplasty to passive 
stenting, the introduction of active stenting did by no means 
FIGURE 3. Coronary angioplasty to >1 vessel area in a single 
session in the European registry from 1992-2003 [12]. Against 
common belief, there was no increase. 
FIGURE 4. Restenosis rates of the Bx-Velocity stent in random-
ized trials when compared with plain balloon angioplasty (to 
the left of the white line) or its new active sibling, the Cypher 
stent (to the right of the white line). The initially favorable re-
stenosis rates (5% and 11%) looked far less favorable (23% to 
43%) when the same passive stent was used as a background for 
the new active stent. This clearly is good for publicity for the 
active stent but is rather difficult to explain.
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improve safety of the procedure. Only this time this was an-
ticipated and made sense. There was even an initial concern 
that late thrombosis may significantly increase as endothelial 
coverage was intentionally curbed and delayed. Fortunately 
this concern did not materialize, although currently some 
voices are raised that perhaps very late thrombosis may be 
increased due to a number of factors, such as incomplete 
coverage of the stent or late allergy to the polymer. In fact, 
mortality at 2 years appeared to be slightly higher with active 
versus passive stents [19], somewhat defying single randomized 
trials or registries yielding overall thrombosis rates below 2%, 
i.e., in the range of passive stents [16].
Moreover, it has to be feared that the beneficial restenosis 
pattern of active stents fosters an overly generous application 
of these modern devices. If too many and too long active stents 
are implanted, late thrombosis rates will inevitably increase. 
The risk of such an event grows at least linearly with every ad-
ditional millimeter of stent. This has to be kept in mind even 
with extreme cases such as the one illustrated in figure 6.
C O N C L U S I O N S  A N D  P E R S P E C T I V E S
Apparently, interventional cardiologists have sold them-
selves to stenting all lesions they perform coronary angioplasty 
upon. Furthermore, they also will use active stents in all cases 
before long. There are no data that support neither of these two 
policies but they are both appealing to operators and patients 
alike. There is even a possibility that the subscription to these 
habits will cost lives in exchange for some patient comfort, 
particularly if the numbers and length of stents implanted get 
out of hand. However, irrational behaving is a human feature 
and thus not estrange to interventional cardiologists either. If 
they insert a drug eluting stent and the outcome is not favor-
FIGURE 5. Summary of randomized trials comparing plain balloon angioplasty (PTCA) to passive stents (stent) in the left panel 
and active stents (DES) to passive stents (BMS) in the right panel. The restenosis rates of passive stents surprisingly increased 
drastically when moving from comparing them with balloon angioplasty to comparing them with the novel active stents. There is 
no plausible explanation for this.
FIGURE 6. Extensive spiral dissection in a right coronary artery 
extending from the first third to the postero-lateral branch (ar-
rows). Provided the flow is unimpeded, such lesions commonly 
healed well with a low potential for immediate and no potential 
for late closure. Today, such a situation is likely to be remedied 
by several active stents with an overall length of 50 mm or more. 
They are not only costly but they carry a substantial risk of late 
thrombosis, a more ominous problem than a restenosis.
able, nobody will blame them for it. If they insert a passive 
stent and the patient has a restenosis, they will be ridiculed. If 
they insert no stent and the patient has a restenosis, let alone 
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an abrupt closure, they will probably be called irresponsible 
and maybe even sued for it. The industry is enchanted and the 
tab is picked up by the patient. 
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